Evidence map›Paper›PMID 39385172›Full record

Observational studyBMC cancer2024

The prognostic role of circulating tumour DNA detected prior to clinical diagnosis of colorectal cancer in the HUNT study.

Siv Stakset Brenne, Poul Henning Madsen, Inge Søkilde Pedersen, Kristian Hveem, Frank Skorpen, Henrik Bygum Krarup, Athanasios Xanthoulis, Eivor Alette Laugsand

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siv Stakset BrenneDepartment of Surgery, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway. siv.s.brenne@ntnu.no.
Poul Henning MadsenClinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Inge Søkilde PedersenClinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Kristian HveemDepartment of Public Health and Nursing, HUNT Research Centre, Norwegian University of Science and Technology, Levanger, Norway.
Frank SkorpenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, N-7489, Norway.
Henrik Bygum KrarupClinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Athanasios XanthoulisDepartment of Surgery, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.
Eivor Alette LaugsandDepartment of Surgery, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundToday, the prognostic tools available at the time of diagnosis in colorectal cancer (CRC) are limited. Better prognostic tools are a prerequisite for personalised treatment. This study aimed to investigate whether circulating tumour DNA (ctDNA) markers found in plasma before clinical diagnosis of CRC could contribute to the prediction of poor prognosis.

methodsThis observational cohort study included patients diagnosed with CRC stage I-III within 24 months following participation in the Trøndelag Health Study (n = 85). Known methylated ctDNA biomarkers of CRC were analysed by PCR in plasma. Outcomes were overall survival (OS), recurrence-free survival (RFS) and poor prognosis (PP). Candidate clinical and methylated ctDNA predictors of the outcomes were identified by Cox regression analyses.

resultsMethylated GRIA4 (HR 1.96 (1.06-3.63)), RARB (HR 9.48 (3.00-30.00)), SLC8A1 (HR 1.97 (1.03-3.77)), VIM (HR 2.95 (1.22-7.14)) and WNT5A (HR 5.83 (2.33-14.56)) were independent predictors of OS, methylated RARB (HR 9.67 (2.54-36.81)), SDC2 (HR 3.38 (1.07-10.66)), SLC8A1 (HR 2.93 (1.01-8.51)) and WNT5A (HR 6.95 (1.81-26.68)) were independent predictors of RFS and methylated RARB (HR 6.11 (1.69-22.18)), SDC2 (HR 2.79 (1.20-6.49)) and WNT5A (HR 5.57 (3.04-15.26)) were independent predictors of PP (p < 0.05).

conclusionsPrediagnostic ctDNA markers are promising contributors to predicting poor prognosis in CRC, potentially becoming one of the tools guiding more personalised treatment.

Indexed as

Biomarkers, TumorCirculating Tumor DNAColorectal NeoplasmsDNA MethylationAgedAged, 80 and overCohort StudiesFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorCirculating Tumor DNACirculating tumour DNAColorectal cancerDNA methylationLiquid biopsyPrognosis

Identifiers

PMID39385172
PMCPMC11465842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.